GenEdit has raised $ 8.5 m in seed funding for its non - viral , nanoparticle delivery system for CRISPR . The funding was led by SK ##tech and Data Collective Bio , with participation from seed funding Bow Capital and Sequoia Capital . Last year , hp ’s CRISPR - mediated treatment was shown to successfully deliver treatment in mouse models of Duchenne muscular dystrophy . It has since broadened its reach . In June , trials showed that hp - Gold could deliver gene editing to the brain and amend the behaviour of mice with Fragile X syndrome , a common single - gene cause of autism spectrum disorder .
GenEdit has raised $8.5m in seed funding for its non-viral, nanoparticle delivery system for CRISPR. The funding was led by SK Holdings and Data Collective Bio, with participation from existing investors Bow Capital and Sequoia Capital. Last year, GenEdit’s CRISPR-Gold treatment was shown to successfully deliver treatment in mouse models of Duchenne muscular dystrophy. It has since broadened its reach. In June, researchers showed that CRISPR-Gold could deliver gene editing to the brain and amend the behaviour of mice with Fragile X syndrome, a common single-gene cause of autism spectrum disorder.